Literature DB >> 9130049

Human cytomegalovirus glycoproteins.

W J Britt1, M Mach.   

Abstract

The complex biology of human cytomegalovirus (HCMV) necessarily begins with an initial interaction between the envelope of the infectious virion and the host cell. Understanding the initial events of infection will require a further analysis of the glycoprotein components of the virion envelope as well as their expression in the membranes of the infected cell. This experimental goal has been hindered by the large genome of HCMV, which may encode over 65 unique glycoproteins. Protein homologs of only 4 herpes simplex virus (HSV) glycoproteins, gB, gH, gL and gM, have been identified, and potential functions have been postulated based on studies of specific glycoprotein null mutants of HSV and other herpesviruses. Additional glycoproteins have been analyzed but to date their function in the replicative cycle of this virus is unknown. Several of the envelope glycoproteins elicit strong host immune responses, including the production of virus-neutralizing antibodies. This response is felt to be a key component of host immunity and represents a goal of vaccine development. Finally, recent findings have also provided evidence that HCMV glycoproteins may contribute to evasion of host cellular immune responses by limiting viral antigen presentation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9130049     DOI: 10.1159/000150510

Source DB:  PubMed          Journal:  Intervirology        ISSN: 0300-5526            Impact factor:   1.763


  67 in total

1.  A protein-based therapeutic for human cytomegalovirus infection.

Authors:  F Jean; L Thomas; S S Molloy; G Liu; M A Jarvis; J A Nelson; G Thomas
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

2.  Fast screening procedures for random transposon libraries of cloned herpesvirus genomes: mutational analysis of human cytomegalovirus envelope glycoprotein genes.

Authors:  U Hobom; W Brune; M Messerle; G Hahn; U H Koszinowski
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

Review 3.  Current and emerging antivirals for the treatment of cytomegalovirus (CMV) retinitis: an update on recent patents.

Authors:  Aswani D Vadlapudi; Ramya K Vadlapatla; Ashim K Mitra
Journal:  Recent Pat Antiinfect Drug Discov       Date:  2012-04

4.  Viral binding-induced signaling drives a unique and extended intracellular trafficking pattern during infection of primary monocytes.

Authors:  Jung Heon Kim; Donna Collins-McMillen; Patrizia Caposio; Andrew D Yurochko
Journal:  Proc Natl Acad Sci U S A       Date:  2016-07-18       Impact factor: 11.205

5.  Antibodies against the gH/gL/UL128/UL130/UL131 complex comprise the majority of the anti-cytomegalovirus (anti-CMV) neutralizing antibody response in CMV hyperimmune globulin.

Authors:  Ashley E Fouts; Pamela Chan; Jean-Philippe Stephan; Richard Vandlen; Becket Feierbach
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

Review 6.  The search for new therapies for human cytomegalovirus infections.

Authors:  Mark N Prichard; Earl R Kern
Journal:  Virus Res       Date:  2010-11-21       Impact factor: 3.303

Review 7.  The diversity of retrotransposons and the properties of their reverse transcriptases.

Authors:  Thomas H Eickbush; Varuni K Jamburuthugoda
Journal:  Virus Res       Date:  2008-02-07       Impact factor: 3.303

8.  Enzyme-linked immunosorbent assay for measurement of cytomegalovirus glycoprotein B antibody in serum.

Authors:  Daniel J Hackett; Changpin Zhang; Carla Stefanescu; Robert F Pass
Journal:  Clin Vaccine Immunol       Date:  2010-03-10

Review 9.  Cytomegalovirus antivirals and development of improved animal models.

Authors:  Alistair McGregor; K Yeon Choi
Journal:  Expert Opin Drug Metab Toxicol       Date:  2011-09-01       Impact factor: 4.481

10.  Human cytomegalovirus UL76 encodes a novel virion-associated protein that is able to inhibit viral replication.

Authors:  Shang-Kwei Wang; Chang-Yih Duh; Cheng-Wen Wu
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.